These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7542379)

  • 1. Adverse pregnancy outcome after a false-positive screen for Down syndrome using multiple markers.
    Pergament E; Stein AK; Fiddler M; Cho NH; Kupferminc MJ
    Obstet Gynecol; 1995 Aug; 86(2):255-8. PubMed ID: 7542379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
    Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ
    J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population.
    Hsieh TT; Hung TH; Hsu JJ; Shau WY; Su CW; Hsieh FJ
    Obstet Gynecol; 1997 Jun; 89(6):937-40. PubMed ID: 9170469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
    Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obstetrical complications associated with abnormal maternal serum markers analytes.
    Gagnon A; Wilson RD;
    J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse perinatal outcome in patients screen-positive for neural tube defects and fetal Down syndrome.
    Gross SJ; Phillips OP; Shulman LP; Bright NL; Dungan JS; Simpson JL; Elias S
    Prenat Diagn; 1994 Jul; 14(7):609-13. PubMed ID: 7526367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study.
    Kellner LH; Weiner Z; Weiss RR; Neuer M; Martin GM; Mueenuddin M; Bombard A
    Am J Obstet Gynecol; 1995 Oct; 173(4):1306-9. PubMed ID: 7485343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.
    MacDonald ML; Wagner RM; Slotnick RN
    Obstet Gynecol; 1991 Jan; 77(1):63-8. PubMed ID: 1701526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
    Benn PA
    Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: A new basis for gestational Down syndrome screening.
    Cole LA; Shahabi S; Oz UA; Bahado-Singh RO; Mahoney MJ
    Clin Chem; 1999 Dec; 45(12):2109-19. PubMed ID: 10585342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes].
    Hu Z; Liu X; Li L; Jia C; Li D; Liu R
    Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of abnormal triple screen for Down syndrome is significantly higher in patients with female fetuses.
    Spong CY; Ghidini A; Stanley-Christian H; Meck JM; Seydel FD; Pezzullo JC
    Prenat Diagn; 1999 Apr; 19(4):337-9. PubMed ID: 10327139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse pregnancy outcomes after a false-positive second trimester serum screen for Down syndrome in Thai pregnant women.
    Sritippayawan S; Vachirasrisoontra C
    J Med Assoc Thai; 2005 Apr; 88(4):449-54. PubMed ID: 16146246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of down syndrome.
    Bahado-Singh R; Oz U; Rinne K; Hunter D; Cole L; Mahoney MJ; Baumgarten A
    Am J Obstet Gynecol; 1999 Oct; 181(4):929-33. PubMed ID: 10521756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
    Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
    Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.
    Wald NJ; Kennard A; Densem JW; Cuckle HS; Chard T; Butler L
    BMJ; 1992 Aug; 305(6850):391-4. PubMed ID: 1382768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
    Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
    Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal serum triple analyte screening and adverse pregnancy outcome.
    Milunsky A; Nebiolo L
    Fetal Diagn Ther; 1996; 11(4):249-53. PubMed ID: 8823604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.